Rapid Therapeutic Science Laboratories, Inc. (RTSL)
Sector: Medical - Pharmaceuticals
Industry: Medical - Pharmaceuticals
Rapid Therapeutic Science Laboratories, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 213 |
| Nov 12, 2026 | 0.0001 | 0.0003 | 0.0001 | 0.0003 | 832 |
Rapid Therapeutic Science Laboratories, Inc. (RTSL) is a biotechnology firm specializing in the aerosolized delivery of non-psychoactive cannabinoids directly into the bloodstream. This innovative approach is aimed at treating various conditions, including chronic pain, post-traumatic stress disorder (PTSD), insomnia, and aiding in surgery recovery, among other health issues. RTSL's product portfolio features pressurized meter dose inhalers (MDIs), designed to precisely dispense an aerosolized mist into the lungs, alongside sublingual oral spray devices. Furthermore, the company offers water-soluble cannabidiol (CBD) and cannabigerol (CBG) isolates under its "nhaler" brand. Established in 2013 and based in Dallas, Texas, the company adopted its current name, Rapid Therapeutic Science Laboratories, Inc., in January 2020, having previously operated as Holly Brothers Pictures, Inc.
It was also formerly a subsidiary of Texas Mdi, Inc.
based on 8.83M shares outstanding
30d Avg
523
60d Avg
523
90d Avg
432
Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) traded at $0.0001 on Nov 13, 2026. 52-week range: $0.0001 to $0.0070. The company is in the Healthcare sector (Medical - Pharmaceuticals).